default author photo

Alexi A. Wright

Harvard University - Dana-Farber Cancer Institute

SCHOLARLY PAPERS

4

DOWNLOADS

108

TOTAL CITATIONS

0

Scholarly Papers (4)

Actions:
Email selected abstracts
1.

Role of Adjuvant Radiotherapy Modality on Clinical Outcomes for Early-Stage Uterine Carcinosarcoma

Number of pages: 20 Posted: 19 Dec 2024
Kevin Tyan, Kevin Liu, Alicia C. Smart, Colleen Feltmate, Neil Horowitz, Michael G. Muto, Michael J. Worley, Kevin M. Elias, Joyce Liu, Alexi A. Wright, Panagiotis A. Konstantinopoulos, Susana M. Campos, Ursula Matulonis, Idalid Franco, Larissa J. Lee, Martin T. King and M. Aiven Dyer
affiliation not provided to SSRN, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Brigham and Women's Hospital, Department of Obstetrics and Gynecology, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, affiliation not provided to SSRN, affiliation not provided to SSRN, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Harvard Medical School, affiliation not provided to SSRN, Harvard University - Dana-Farber Cancer Institute and affiliation not provided to SSRN
Downloads 58 (980,173)

Abstract:

Loading...

uterine carcinosarcoma, adjuvant radiation, external beam radiotherapy, vaginal brachytherapy, EBRT, VBT

2.

Survival Benefit of Universal Homologous Recombination Deficiency Testing in Ovarian Cancer Patients

Number of pages: 23 Posted: 16 Jun 2026
Claudia L. Seguin, Andrew Eckel, Clare E. Wiberg, Ling Chen, Joel Agarwal, Jennifer S. Ferris, Alexi A. Wright, Mary Linton B. Peters, Amy B. Knudsen, Jason Wright and Pari V. Pandharipande
Stanford University, affiliation not provided to SSRN, affiliation not provided to SSRN, Tufts University - Tufts Medical Center, Columbia University College of Physicians and Surgeons, Columbia University College of Physicians and Surgeons, Harvard University - Dana-Farber Cancer Institute, Harvard University - Massachusetts General Hospital, Harvard University - Massachusetts General Hospital, Tufts University - Tufts Medical Center and affiliation not provided to SSRN
Downloads 18

Abstract:

Loading...

decision analysis, advanced ovarian cancer, homologous recombination deficient tumors, poly(ADP-ribose) polymerase inhibitors

3.

The impact of comorbidity and guideline-concordant care on survival in ovarian cancer patients

Number of pages: 24 Posted: 14 Jan 2026
Jennifer S. Ferris, Joel Agarwal, Ling Chen, Yongmei Huang, Claudia L. Seguin, Andrew Eckel, Clare E. Wiberg, Alexi A. Wright, Mary Linton B. Peters, Amy B. Knudsen, Pari V. Pandharipande and Jason D. Wright
Columbia University College of Physicians and Surgeons, Columbia University College of Physicians and Surgeons, Columbia University College of Physicians and Surgeons, Columbia University College of Physicians and Surgeons, Stanford University, affiliation not provided to SSRN, affiliation not provided to SSRN, Harvard University - Dana-Farber Cancer Institute, affiliation not provided to SSRN, Harvard University - Massachusetts General Hospital, affiliation not provided to SSRN and Columbia University - Irving Medical Center
Downloads 17 (1,509,872)

Abstract:

Loading...

Comorbidity, Treatment, guidelines, ovarian cancer, interaction

4.

Phase 2 Study of Wee1 Inhibitor Adavosertib in Recurrent Uterine Carcinosarcoma

Number of pages: 32 Posted: 03 Jun 2025
Stephanie Cham, Niya Xiong, Nabihah Tayob, Carolyn Krasner, Alexi A. Wright, Elizabeth Katherine Lee, Hannah Sawyer, Cara A. Mathews, Panagiotis A. Konstantinopoulos, Ursula Matulonis and Joyce Liu
affiliation not provided to SSRN, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Brown University - Department of Obstetrics and Gynecology, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute and Harvard University - Dana-Farber Cancer Institute
Downloads 15 (1,500,778)

Abstract:

Loading...

uterine carcinosarcoma, Wee1 inhibitor, TP53 mutation, phase 2 trial, next generation sequencing